| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
|
Medicine details |
|
| Medicine name | rifaximin (Targaxan®) |
| Formulation | 550 mg film-coated tablet |
| Reference number | 1058 |
| Indication | Reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age |
| Company | Norgine Pharmaceuticals Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/11/2012 |
| NICE guidance | TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |